Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients
暂无分享,去创建一个
H. Gogas | G. Aravantinos | A. Bamias | A. Stratigos | A. Charpidou | V. Nikolaou | D. Rigopoulos | E. Samantas | I. Triantafyllopoulou | D. Voudouri | G. Tsironis | G. Stamoulis | I. Panoutsopoulou | E. Xidakis | K. Syrigos
[1] H. Babey,et al. Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review , 2018, Expert review of anticancer therapy.
[2] G. Aravantinos,et al. Anti-PD1/PDL1 induced psoriasis. , 2017, Current problems in cancer.
[3] C. Bai,et al. Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma , 2017, Respiratory medicine case reports.
[4] V. Velcheti,et al. To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] S. Yokota,et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. , 2017, Lung cancer.
[6] M. Larsabal,et al. Vitiligo‐like lesions occurring in patients receiving anti‐programmed cell death–1 therapies are clinically and biologically distinct from vitiligo , 2017, Journal of American Academy of Dermatology.
[7] G. Jeudy,et al. Anti‐PD1‐induced psoriasis: a study of 21 patients , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] M. Saif,et al. Incidence and implications of chemotherapy related hand-foot syndrome , 2016, Expert opinion on drug safety.
[9] K. Kabashima,et al. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[10] P. Hegde,et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Lacouture,et al. Dermatological adverse events with taxane chemotherapy , 2016, European Journal of Dermatology.
[12] J. Wolchok,et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.
[13] K. Byth,et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. , 2016, Journal of the American Academy of Dermatology.
[14] Toshiyuki Yamamoto,et al. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma. , 2016, Acta dermato-venereologica.
[15] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[16] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[18] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[19] F. Camacho,et al. The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology. , 2015, The oncologist.
[20] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[21] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[22] Christopher J. Miller,et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. , 2012, Journal of the American Academy of Dermatology.
[23] M. Alter,et al. The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[24] M. Tanioka,et al. Prospective Study of Ice Gel Pack as Less Expensive Alternative for Prevention of Skin and Nail Toxicity in Patients with Breast Cancer Receiving Docetaxel. , 2009 .
[25] M. Lacouture,et al. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis , 2008, Acta oncologica.
[26] S. Yashar,et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. , 2007, Journal of the American Academy of Dermatology.
[27] M. Markman. Managing taxane toxicities , 2003, Supportive Care in Cancer.
[28] C. Aring,et al. A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.
[29] J. Soria,et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.
[30] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.